Kevin Unger, MD
Urology · Cambridge, MNNPI 1497721138
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.9%), travel and lodging and education — rather than concentrated in one kind of arrangement. Procept Biorobotics Corporation accounts for 63.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $1,154 and has fallen 89.1% since, to $125 in 2025.
Across 16 payments — averaging $112.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$1K
- Teleflex LLC$286
- Laborie Medical Technologies Corp.$125
- Olympus America Inc.$122
- AbbVie$57
- Telix Pharmaceuticals$48
- plus $12 from 1 others
What the payments were for
- Travel & lodging$76542%
- Food & beverage$1,02757%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 6 | $1,154 |
| Teleflex LLC | 2 | $286 |
| Laborie Medical Technologies Corp. | 2 | $125 |
| Olympus America Inc. | 1 | $122 |
| AbbVie(2 entities) | 3 | $57 |
| Telix Pharmaceuticals | 1 | $48 |
| Urogen Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$1,019
- UroLift$149
- UroLift System$136
- iTIND System$122
How this compares
$1,804 in reported general payments places this provider in the 60th percentile of 247 urology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 59 | $31,711 |
| Tamsulosin Hcl | 87 | $1,499 |
| Finasteride | 31 | $354 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 25 | $337 |
| Oxybutynin Chloride ErOxybutynin Chloride | 44 | $289 |
| Ciprofloxacin Hcl | 44 | $121 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 31 | $75 |
Paid to pharmacies, not to this prescriber.
Other urology in Cambridge
- David YangMankato$298K
- Steven BernsteinEdina$271K
- Ayman SoubraMinneapolis$204K
- Sean ElliottMinneapolis$163K
- Jonathan WarnerRochester$144K
- Steven SiegelWoodbury$140K
- Aaron MilbankWoodbury$97K
- Tobias KohlerRochester$89K
- Joseph MahonEdina$86K
- Nissrine NakibMinneapolis$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.